文献速递膀胱癌与上尿路尿路上皮癌

非转移性浆细胞样变异型膀胱癌患者的长期肿瘤学结局:德克萨斯大学MD安德森癌症中心20年经验

Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
PubMed 文献 · J Urol · 2023-11-03

该回顾性队列纳入1998至2018年在单中心接受根治性治疗的56例非转移性浆细胞样变异型膀胱癌患者,36个月随访时28.4%存活、22.2%无转移,腹膜是最主要复发转移部位(76.1%),挽救性免疫治疗与死亡风险降低相关(HR=0.11,P=.001)。

要点

  • 56例非转移性浆细胞样变异型膀胱癌接受根治性治疗,36个月时仅22.2%无转移生存。
  • 腹膜是最常见复发转移部位(76.1%),可孤立或伴腹膜外病灶。
  • 局限/局部晚期患者完成手术与转移无生存改善相关(36个月32.4% vs 0%,P<.001)。

核心结论

  • 浆细胞样变异型膀胱癌致死性高,多数患者治疗后早期出现非典型腹膜内转移并迅速死亡。
  • 作者认为,在该高危人群中评估腹腔热灌注化疗和/或免疫治疗价值的临床试验可能有必要。

研究设计与样本

  • 单中心回顾性病历审查,经自然语言处理算法辅助,纳入1998至2018年在该机构接受根治性治疗的56例连续非转移性浆细胞样变异型膀胱癌患者。
  • 采用Kaplan-Meier法和多变量Cox回归进行生存分析。

主要发现

  • 初诊分期:≤cT2N0为22例(39.3%),cT3N0为15例(26.8%),cT4N0为13例(23.2%),≥cN1为6例(10.7%)。
  • 49例(87.5%)接受化疗,42例(75%)能够接受计划手术;仅4例(7.2%)为pT0期,22例(52.4%)手术时为pN+。
  • 36个月随访时,28.4%(95%CI:22.1%-34.5%)存活,22.2%(95%CI:16.1%-28.5%)无转移生存。
  • 局限或局部晚期(≤cT2N0/cT3N0)患者中,成功完成手术与转移无生存改善相关(36个月32.4% vs 0%,log-rank P<.001);区域晚期(cT4N0/≥cN1)患者中,化疗后巩固手术未与转移无生存改善相关(36个月12.5% vs 10%,log-rank P=.49)。
  • 自主要治疗结束至转移的中位时间为6.5个月(IQR:2.9-14.7);主要复发/转移部位为腹膜(76.1%),可孤立或伴腹膜外病灶;挽救性免疫治疗显著降低死亡风险(HR=0.11,P=.001)。

临床怎么用

  • 作者认为,在该高危人群中评估腹腔热灌注化疗和/或免疫治疗价值的临床试验可能有必要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The treated natural history of nonmetastatic plasmacytoid variant of bladder cancer (PV-BCa) is poorly understood owing to its rarity. We sought to examine the disease recurrence and metastasis patterns in this select group of patients in order to identify opportunities for intervention. MATERIALS AND METHODS: We conducted a natural language processing algorithm-augmented retrospective chart review of 56 consecutive patients who were treated with curative intent for nonmetastatic PV-BCa at our institution between 1998 and 2018. Kaplan-Meier and multivariable Cox regression methods were used for survival analyses. RESULTS: The stage at presentation was: ≤ cT2N0 in 22 (39.3%), cT3N0 in 15 (26.8%), cT4N0 in 13 (23.2%), and ≥ cN1 in 6 patients (10.7%). Forty-nine patients (87.5%) received chemotherapy, and 42 (75%) were able to undergo the planned surgery. Notably, only 4 patients (7.2%) had pT0 stage, while 22 (52.4%) had pN+ disease at the time of surgery. At 36-month follow-up, 28.4% of patients (95% CI: 22.1%-34.5%) were alive and 22.2% (95% CI: 16.1%-28.5%) were free of metastatic disease. The benefit of surgical extirpation was stage specific: successful completion of surgery was associated with improved metastasis-free survival (at 36 months 32.4% vs 0%, log-rank P < .001) in patients with localized or locally advanced disease (≤cT2N0/cT3N0); however, in patients with regionally advanced disease (cT4N0/≥cN1), consolidative surgery following chemotherapy was not associated with improved metastasis-free survival (12.5% vs 10% at 36 months, log-rank P = .49). The median time to metastasis from primary treatment end was 6.5 months (IQR: 2.9-14.7). The predominant site of recurrence/metastasis was the peritoneum (76.1%), either in isolation or along with extraperitoneal lesions. Salvage immunotherapy in these patients significantly reduced the risk of death (HR = 0.11, P = .001). CONCLUSIONS: PV-BCa is a disease with high lethality. Despite multimodal treatment, a vast majority of patients develop atypical intraperitoneal metastasis soon after therapy and rapidly succumb to it. Clinical trials evaluating utility of hyperthermic intraperitoneal chemotherapy and/or immunotherapy may be warranted in this high-risk population.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Sood A, Rudzinski JK, Labbate CV, et al. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2023. PMID: 37922370. doi:10.1097/JU.0000000000003778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。